Centerpoint Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Centerpoint Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,000	Closed	-$375K	–	474
2024 Q1	$375K	Hold	27,000	–	–	0.14%	57
2023 Q4	$385K	Hold	27,000	–	–	0.15%	55
2023 Q3	$418K	Hold	27,000	–	–	0.18%	53
2023 Q2	$424K	Hold	27,000	–	–	0.17%	54
2023 Q1	$445K	Hold	27,000	–	–	0.19%	49
2022 Q4	$421K	Hold	27,000	–	–	0.2%	48
2022 Q3	$350K	Sell	27,000 -372	-1%	-$5.17K	0.19%	51
2022 Q2	$384K	Buy	27,372 +372	+1%	+$5.31K	0.2%	52
2022 Q1	$387K	Hold	27,000	–	–	0.18%	53
2021 Q4	$368K	Sell	27,000 -3,700	-12%	-$51.9K	0.16%	59
2021 Q3	$503K	Hold	30,700	–	–	0.24%	45
2021 Q2	$517K	Sell	30,700 -14,026	-31%	-$239K	0.24%	43
2021 Q1	$817K	Hold	44,726	–	–	0.48%	25
2020 Q4	$814K	Hold	44,726	–	–	0.53%	25
2020 Q3	$798K	Hold	44,726	–	–	0.6%	25
2020 Q2	$802K	Hold	44,726	–	–	0.65%	24
2020 Q1	$679K	Hold	44,726	–	–	0.68%	23
2019 Q4	$882K	Buy	+44,726	New	+$856K	0.65%	21

Other funds holding TAK

GAM

Groupama Asset Management Paris, France $6.85B AUM 43.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Centerpoint Advisors's TAK Position: Q2 2024 in Review

Centerpoint Advisors sold out of Takeda Pharmaceutical (TAK) in Q2 2024, closing a stake of 27,000 shares — an estimated $375K sold.

Centerpoint Advisors first reported a position in TAK in Q4 2019 and held it in 18 quarters. The position peaked at $882K in Q4 2019. 284 funds tracked by Wall St. Rank hold TAK as of Q2 2024.

Centerpoint Advisors reported no remaining Takeda Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Centerpoint Advisors sold 27,000 Takeda Pharmaceutical shares in Q2 2024, an estimated $375K.
Centerpoint Advisors first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 18 quarters.
Centerpoint Advisors's Takeda Pharmaceutical position peaked at $882K in Q4 2019.
284 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2024.

Based on Centerpoint Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.